Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 11;1(2):57-62.
doi: 10.1016/j.jbo.2012.06.002. eCollection 2012 Sep.

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

J E Lester  1 , D Dodwell  2 , J E Brown  3 , O P Purohit  1 , S A Gutcher  1 , S P Ellis  1 , R Thorpe  1 , J M Horsman  4 , R E Coleman  4
Affiliations

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

J E Lester et al. J Bone Oncol. .

Abstract

Purpose: The ARIBON trial is a double blind, randomised, placebo controlled study designed to evaluate the impact of ibandronate on bone mineral density (BMD) in women taking anastrozole for adjuvant treatment of breast cancer.

Methods: 131 postmenopausal women with early breast cancer were recruited to the study. Of these, 13 had osteoporosis, 50 osteopenia and 68 normal BMD. Patients with osteoporosis at baseline were treated with monthly oral ibandronate 150 mg for 5 years; osteopenic patients were randomised to receive either ibandronate or placebo for two years and offered open label ibandronate depending upon the results of their 2-year BMD result.

Results: Of the 20 patients with osteopenia who were randomised to ibandronate and evaluable at the 2 year visit, 17/20 were not offered a bisphosphonate and the improvements in BMD accrued during the first 2 years were lost both at the LS (-3.21%) and TH (-5.0%). Of the 16 patients randomised to placebo 8/16 with high rates of bone loss during years 0-2 received ibandronate over the next 3 years with improvements in BMD of +5.01 and +1.19 at the LS and TH respectively. The 8 patients who were not offered a bisphosphonate experienced relatively little change in BMD throughout the 5 years of the study (LS +0.15%, TH -2.72%). BMD increased steadily in the 9/13 patients initially identified as having osteoporosis (LS +9.65%, TH +2.72%).

Conclusions: Monthly oral ibandronate provides an option to clinicians considering use of a bisphosphonate to prevent bone loss during aromatase inhibitor therapy.

Keywords: Aromatase inhibitor; Bone; Breast; Cancer; Osteoporosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Consort diagram showing the number of patients recruited and those included in the analysis.
Fig. 2
Fig. 2
Mean percentage change in LS and TH BMD from baseline (95% Confidence Intervals). (A) Ibandronate-Placebo. (B) Placebo-Ibandronate. (C) Osteoporosis.
Fig. 3
Fig. 3
Changes in BMD groupings for all osteopenic patients.
See this image and copyright information in PMC

References

    1. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. - PubMed
    1. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology. 2010;11:1135–1141. - PubMed
    1. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570. - PubMed
    1. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine. 2005;353:2747–2757. - PubMed
    1. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. Journal of Clinical Oncology. 2007;25:486–492. - PubMed